911069-02-8

Basic information

• Product Name: Butanoic acid, 4-oxo-3-[[(phenylmethoxy)carbonyl]amino]-4-[[(1R)-1-[3-(trifluoromethyl) phenyl]ethyl]amino]-, 1,1-dimethylethyl ester, (3R)-
• CAS NO: 911069-02-8
• Molecular Formula: C25H29F3N2O5
• Molecular Weight: 494.511
• Mol File: 911069-02-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Butanoic acid, 4-oxo-3-[[(phenylmethoxy)carbonyl]amino]-4-[[(1R)-1-[3-(trifluoromethyl) phenyl]ethyl]amino]-, 1,1-dimethylethyl ester, (3R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 4-oxo-3-[[(phenylmethoxy)carbonyl]amino]-4-[[(1R)-1-[3-(trifluoromethyl) phenyl]ethyl]amino]-, 1,1-dimethylethyl ester, (3R)-(911069-02-8)
• EPA Substance Registry System: Butanoic acid, 4-oxo-3-[[(phenylmethoxy)carbonyl]amino]-4-[[(1R)-1-[3-(trifluoromethyl) phenyl]ethyl]amino]-, 1,1-dimethylethyl ester, (3R)-(911069-02-8)

Safety Data

• Hazardous Substances Data: 911069-02-8(Hazardous Substances Data)

Upstream product

• 127852-30-6 (R)-α-(m-(trifluoromethyl)phenyl)ethylamine 
• 71449-08-6 (2R)-2-{[(benzyloxy)carbonyl]amino}-4-tert-butoxy-4-oxobutanoic acid 

Downstream Products

• 911068-20-7 3-[2-oxo-3-(2-oxo-4-phenyl-oxazolidin-3-yl)-4-styryl-azetidin-1-yl]-N-[1-(3-trifluoromethyl-phenyl)-ethyl]-succinamic acid tert-butyl ester 
• 911068-29-6 3-[2-oxo-3-(2-oxo-4-phenyl-oxazolidin-3-yl)-4-styryl-azetidin-1-yl]-N-[1-(3-trifluoromethyl-phenyl)-ethyl]-succinamic acid 
• 911069-05-1 D-aspartic acid β-tert-butyl ester α-{[(R)-1-(trifluoromethyl)phenyl]ethyl}amide 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY

Compounds, and compositions, methods, and uses thereof, are described herein for treating brain injuries.

METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER

Compounds and compositions are described herein for treating post tramatic stress disorder.

β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS

β-lactamyl alkanoic acids and pharmaceutical compositions thereof are described. Methods for treating various diseases and disease states using one or more β-lactamyl alkanoic acids are also described. Substituted 2-(azetidin-2-on-l-yl)alkanedioic acids,